--- title: "Aptevo Highlights Strong Phase 1b AML Trial Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/285438013.md" description: "Aptevo Therapeutics reported promising results from its RAINIER Phase 1b trial for acute myeloid leukemia, showing an 87% clinical benefit rate and 81% remission in 31 patients. The trial, which combines mipletamig with venetoclax and azacitidine, is in its final dose-optimization stage, with a recommended Phase 2 dose expected in 2026. The results indicate mipletamig's potential as a frontline treatment, especially for older patients with high-risk mutations. Despite positive clinical data, analysts express concerns over Aptevo's financial performance, rating the stock as Neutral with a $21.00 price target." datetime: "2026-05-06T20:52:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285438013.md) - [en](https://longbridge.com/en/news/285438013.md) - [zh-HK](https://longbridge.com/zh-HK/news/285438013.md) --- # Aptevo Highlights Strong Phase 1b AML Trial Results ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Aptevo Therapeutics ( (APVO) ) has provided an update. On May 6, 2026, Aptevo reported new data from its RAINIER Phase 1b frontline acute myeloid leukemia trial showing that mipletamig, combined with venetoclax and azacitidine, achieved an 87% clinical benefit rate and 81% remission in 31 evaluable patients, substantially outperforming historical benchmarks while maintaining a favorable safety profile with no cytokine release syndrome. With Cohort 5 complete and the program now in its final dose-optimization stage, the company expects to finish the Phase 1b trial and select a recommended Phase 2 dose in 2026, positioning mipletamig—already granted U.S. orphan drug status for AML—as a potentially more effective frontline option for older or unfit patients, including those with high-risk TP53 mutations, and enabling progression to allogeneic stem cell transplant for some participants. The data set also highlighted deep responses, with more than half of remissions reaching measurable residual disease-negative status and six patients proceeding to allogeneic stem cell transplant, a best-case outcome rarely seen in this frail population. These results support mipletamig’s differentiated CD123-targeting design and suggest a competitive edge against current venetoclax plus azacitidine standards, reinforcing Aptevo’s strategic positioning in AML and its broader immuno-oncology pipeline. The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page. **Spark’s Take on APVO Stock** According to Spark, TipRanks’ AI Analyst, APVO is a Neutral. The score is primarily weighed down by very weak financial performance (zero revenue, sustained losses, and heavy cash burn). Technicals are mixed with short-term strength but longer-term downtrend signals. Corporate events provide some upside from encouraging clinical data and improved financing flexibility, but valuation remains unsupported due to losses and no dividend. To see Spark’s full report on APVO stock, click here. **More about Aptevo Therapeutics** Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel bispecific and trispecific immunotherapies for cancer. The Seattle-based firm has two clinical and six preclinical candidates targeting a range of solid tumors, all built on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with a mission to improve treatment outcomes and transform the lives of cancer patients. **Average Trading Volume:** 47,715 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $6.44M For a thorough assessment of APVO stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [APVO.US](https://longbridge.com/en/quote/APVO.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategy](https://longbridge.com/en/news/293969770.md) - [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md) - [Aptevo Therapeutics posts investor presentation on multispecific immunotherapies for cancer, led by mipletamig in AML](https://longbridge.com/en/news/290859040.md) - [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md) - [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md)